Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754271 | 0.85 | ALDH1A1 (0.44) | — | |
| SCHEMBL2752143 | 0.81 | RXRA (0.36) | CYP11B2 | |
| SCHEMBL21815522 | 0.81 | EGLN2 (0.41) | CYP11B1CYP11B2EGLN2KDM4EKMT2A | |
| SCHEMBL28719969 | 0.77 | KCNH2 (0.39) | CYP11B2EGLN2 | |
| SCHEMBL2075610 | 0.76 | S1PR3 (0.43) | TRPV4CYP11B1CYP11B2EGLN2KDM4E | |
| SCHEMBL6852366 | 0.76 | GRM5 (0.46) | TRPV4CYP11B1CYP11B2EGLN2KDM4E | |
| SCHEMBL2528828 | 0.75 | TRPV4 (0.47) | TRPV4CYP11B1CYP11B2EGLN2KDM4E | |
| SCHEMBL21609086 | 0.73 | NOTUM (0.53) | TRPV4CYP11B1CYP11B2EGLN2 | |
| SCHEMBL31605575 | 0.73 | NOTUM (0.53) | TRPV4CYP11B1CYP11B2EGLN2 | |
| SCHEMBL7229570 | 0.72 | NOTUM (0.44) | CYP11B1CYP11B2EGLN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3856348-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | Incyte Corporation (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068729-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | INCYTE CORPORATION (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | TRPV4 2610/4885CYP11B1 1176/4885CYP11B2 636/4885 |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | TRPV4 2610/4885CYP11B1 1176/4885CYP11B2 636/4885 |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | TRPV4 2610/4885CYP11B1 1176/4885CYP11B2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.